383 related articles for article (PubMed ID: 37102247)
21. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies : Position paper of the Heart Failure Working Group of the Austrian Society of Cardiology.
Bergler-Klein J; Rainer PP; Wallner M; Zaruba MM; Dörler J; Böhmer A; Buchacher T; Frey M; Adlbrecht C; Bartsch R; Gyöngyösi M; Fürst UM
Wien Klin Wochenschr; 2022 Sep; 134(17-18):654-674. PubMed ID: 35507087
[TBL] [Abstract][Full Text] [Related]
22. Cardio-Oncology: An Update on Cardiotoxicity of Cancer-Related Treatment.
Lenneman CG; Sawyer DB
Circ Res; 2016 Mar; 118(6):1008-20. PubMed ID: 26987914
[TBL] [Abstract][Full Text] [Related]
23. Emergence of cardio-oncology.
Nebigil CG; Désaubry L
Ann Pharm Fr; 2018 Nov; 76(6):504-506. PubMed ID: 30075937
[TBL] [Abstract][Full Text] [Related]
24. Cardiac Complications in the Adult Bone Marrow Transplant Patient.
Tuzovic M; Mead M; Young PA; Schiller G; Yang EH
Curr Oncol Rep; 2019 Mar; 21(3):28. PubMed ID: 30826891
[TBL] [Abstract][Full Text] [Related]
25. Cardio-oncology for Pediatric and Adolescent/Young Adult Patients.
Tolani D; Wilcox J; Shyam S; Bansal N
Curr Treat Options Oncol; 2023 Aug; 24(8):1052-1070. PubMed ID: 37296365
[TBL] [Abstract][Full Text] [Related]
26. Cardio-oncology Part II: the monitoring, prevention, detection and treatment of chemotherapeutic cardiac toxicity.
O'Hare M; Murphy K; Mookadam F; Sharma A; Lee H
Expert Rev Cardiovasc Ther; 2015 May; 13(5):519-27. PubMed ID: 25864865
[TBL] [Abstract][Full Text] [Related]
27. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
28. [Treatment recommendations in cardio-oncology: where are we?].
Müller OJ; Baldus CD
Internist (Berl); 2020 Nov; 61(11):1125-1131. PubMed ID: 33025122
[TBL] [Abstract][Full Text] [Related]
29. [Mechanisms of cardiotoxicity of oncological therapies].
Lehmann LH; Fröhling S
Internist (Berl); 2020 Nov; 61(11):1132-1139. PubMed ID: 33034675
[TBL] [Abstract][Full Text] [Related]
30. [Update cardio-oncology : Immune checkpoint inhibitor therapy].
Michel L; Rassaf T
Herz; 2024 Feb; 49(1):81-90. PubMed ID: 38175285
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
32. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs.
Beyer AM; Bonini MG; Moslehi J
Am J Physiol Heart Circ Physiol; 2019 Jul; 317(1):H164-H167. PubMed ID: 31172808
[TBL] [Abstract][Full Text] [Related]
33. Cardio-oncology: the role of advanced echocardiography in cancer patients.
Venneri L; Zoppellaro G; Khattar RS
Expert Rev Cardiovasc Ther; 2018 Apr; 16(4):249-258. PubMed ID: 29457984
[TBL] [Abstract][Full Text] [Related]
34. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
35. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
36. Role of cardiovascular magnetic resonance imaging in cardio-oncology.
Saunderson CED; Plein S; Manisty CH
Eur Heart J Cardiovasc Imaging; 2021 Mar; 22(4):383-396. PubMed ID: 33404058
[TBL] [Abstract][Full Text] [Related]
37. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
38. Antineoplastic drugs inducing cardiac and vascular toxicity - An update.
Barachini S; Ghelardoni S; Varga ZV; Mehanna RA; Montt-Guevara MM; Ferdinandy P; Madonna R
Vascul Pharmacol; 2023 Dec; 153():107223. PubMed ID: 37678516
[TBL] [Abstract][Full Text] [Related]
39. Identifying cancer patients at risk for cardiotoxicity.
Salvatici M; Sandri MT
Future Oncol; 2015; 11(14):2077-91. PubMed ID: 26198838
[TBL] [Abstract][Full Text] [Related]
40. Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity.
Wickramasinghe CD; Nguyen KL; Watson KE; Vorobiof G; Yang EH
Future Oncol; 2016 Mar; 12(6):855-70. PubMed ID: 26829050
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
